TP53 and cancer: APR-246 was reported to exert such an activity, and this compound is currently undergoing clinical trials in several cancer types but only in cases expressing mutant TP53 (ClinicalTrials.gov Identifier: NCT02999893, NCT03931291, NCT04214860 and NCT04383938) [10].